1Rose FV,Barnea ER. Response of human ovarian carcinoma cell lines to antiprogestin mifepristone [J]. Oncogene,1996,12(5):999- 1003.
2Rocereto TF,Saul HM,Aikins JA Jr,et al. Phase Ⅱ study of mifepristone (RU486) in refractory ovarian cancer [J]. Gynecol Oncol, 2000, 77(3):429- 432.
3Arango H,Satyaswaroop P,Cavaagh D,et al. The growth inhibitory effects of onapristone(ZK98299) and mifepristone(RU486) on the iskikawa human endometrial cancer cell line [J]. Gynecol Oncol,1996,62(3):423.
4Schneider CC,Gibb RK,Taylor DD,et al. Inhibition of endometrial cancer cell lines by mifepristone (RU 486) [J]. J Soc Gynecol Investig,1998,5(6):334- 338.
5Webster K,Taylor A,Gaston K. Oestrogen and progesterone increase the levels of apoptosis induced by the human papillomavirus type 16 E2 and E7 proteins [J]. J Gen Virol,2001,82(Pt 1):201- 213.
6El Etreby MF,Liang Y,Lewis RW. Induction of apoptosis by mifepristone and tamoxifen in human LNCaP prostate cancer cells in culture [J]. Prostate,2000,43(1):31- 42.
7El Etreby MF,Liang Y,Wrenn RW,et al. Additive effect of mifepristone and tamoxifen on apoptotic pathways in MCF-7 human breast cancer cells [J]. Breast Cancer Res Treat,1998,51(2):149- 68.
8Fardel O,Courtois A,Drenou B,et al. Inhibition of P-glycoprotein activity in human leukemic cells by mifepristone [J]. Anticancer Drugs, 1996, 7(6):671- 677.
9Payen L,Delugin L,Courtois A,et al. Reversal of MRP-mediated multidrug resistance in human lung cancer cells by the antiprogestation drug RU486 [J].Biochem Biophys Res Commun,1999,258(3):513- 518.
10Liu YY,Han TY,Giuliano AE,et al. Expression of glucosylceram-ide synthase,converting ceramide to glucosylceramide,confers adriamycin resistance in human breast cancer cells [J]. J Biol Chem,1999,274(21):1140- 1146.
